AlphAIAlphAI — Financial news for AI agents
tipranks.com$PDSB

PDS Biotech Announces NantWorks Warrant Exercise Raising $3.9 Million

PDS Biotech (PDSB) announced that NantWorks exercised warrants to buy 17.7 million shares at $0.22 each, raising $3.9 million. The warrants were part of a September 2026 private placement that generated $11.3 million. Analysts have a Buy rating with a $4.00 target, but TipRanks' AI rates it Neutral due to financial weaknesses and technical strengths.

Original reporting
tipranks.com
Published Nov 10, 2026, 1:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 2:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Neutral
medium confidence
Mentioned
$PDSB
Relevance
5/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$PDSBNeutralLow
01

Why it matters

The $3.9M proceeds improve short‑term liquidity but are unlikely to change the company's long‑term valuation without accompanying clinical data.

02

Market read

A modest financing event for a micro‑cap biotech; limited immediate trading impact.

03

What to watch

Pre‑funded warrants dilute existing shareholders at a near‑zero price, which could offset the cash benefit.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

PDS Biotechnology is a clinical‑stage biotech with no revenue and ongoing cash burn. The warrant exercise follows a private placement that raised $11.3M earlier.

Company-level read

Ticker impact

$PDSBNeutralMedium confidence
Context

NantWorks exercised warrants for 17.7M shares at $0.22, raising $3.9M in gross proceeds for PDS Biotechnology.

Expected impact

likely slight upward pressure as the market prices in the new capital raise

Evidence & confidence

A micro‑cap financing event provides fresh cash but the amount ($3.9M) is modest versus the $129M market cap, limiting price move.

Market effects

Sector

Minimal; biotech financing news may slightly boost sentiment for early‑stage biotech issuers.

Regional

US micro‑cap market only.

Global

Low; no broader macro impact.

Counterpoint

What could challenge this read

The raise may be seen as a sign of cash strain, suggesting potential downside if burn continues.

Key entities

  • company
    PDS Biotechnology

    Clinical‑stage biotech developing immunotherapies.

  • investor
    NantWorks

    Entity exercising warrants in PDSB.

Read at source← All news

Related articles

$PDSBHighAI 8/10

B.Riley raises PDS Biotechnology stock price target on trial data

B.Riley raised its price target for PDS Biotechnology (PDSB) to $4.00 from $3.00, maintaining a Buy rating. The stock has gained 97% year-to-date, trading at $1.52. The upgrade follows positive trial data for PDS0301 in liver-metastatic colorectal cancer. PDSB plans to submit a Phase 3 protocol by Q4 2024, with a trial start in Q1 2027. The company also announced leadership changes and a share structure amendment.

investing.com
$PDSBMedAI 8/10

PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

tradingview.com
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com